Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607550 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
A Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, sponsored by ArriVent BioPharma.
- Active
- Registry status
- Phase 3
- Development phase
- 398
- Enrollment target
- 20
- Study locations
NCT05607550 is a Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by ArriVent BioPharma. The registered enrollment target is 398 participants, roughly in line with the 380-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 6 states.
The verdict
NCT05607550, a Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by ArriVent BioPharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 398 participants
- Enrollment target
- 20
- Study locations
Study Summary
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.
Conditions Studied
Interventions
- DRUG furmonertinib 240 mg oral, daily
- DRUG furmonertinib 160 mg oral, daily
- DRUG platinum-based chemotherapy
Study Locations (20)
California
- Arrivent Investigative Site - Beverly Hills
- Arrivent Investigative Site - Fullerton
- Arrivent Investigative Site - Long Beach
- Arrivent Investigative Site - Los Alamitos
- Arrivent Investigative Site - Napa
- Arrivent Investigative Site - Orange
- Arrivent Investigative Site - Orange
- Arrivent Investigative site - Sacramento
- Arrivent Investigative Site - San Diego
- Arrivent Investigative Site - Santa Barbara
- Arrivent Investigative Site - Santa Monica
- Arrivent Investigative Site - Santa Rosa
- Arrivent Investigative Site - Whittier
Connecticut
- Arrivent Investigative Site - Hartford
- Arrivent Investigative Site - Norwich
Florida
- Arrivent Investigative Site - Fort Myers
- Arrivent Investigative Site - St. Petersburg
Alabama
- Arrivent Investigative Site - Daphne
Arizona
- Arrivent Investigative Site - Yuma
Arkansas
- Arrivent Investigative Site - Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2028-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05607550
The ClinicalTrials.gov registry entry for NCT05607550 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 398 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 380-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is ArriVent BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which furmonertinib 240 mg oral, daily is the first listed.
NCT05607550 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT05607550 about?
NCT05607550 is a clinical study titled "Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)". Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-sq...
What is the current status of trial NCT05607550?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 398 participants. The study started on 2023-06-01. Estimated completion is 2028-02-15.
What conditions does trial NCT05607550 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR Exon 20 Mutations.
What interventions are being tested in trial NCT05607550?
The interventions under investigation include: furmonertinib 240 mg oral, daily (DRUG), furmonertinib 160 mg oral, daily (DRUG), platinum-based chemotherapy (DRUG).
Who is sponsoring clinical trial NCT05607550?
This trial is sponsored by ArriVent BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607550 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RECRUITING · Phase 3
-
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Metastatic Non Small Cell Lung Cancer
All registered trials for this condition
Advanced Non-Small-Cell Lung Cancer
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.